Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

ELVN

$44.83

Updated: 03/11/2026, 23:29:22

Market Cap
$3.28B
Sector
Healthcare
Industry
Biotechnology
Country
US

No historical data available

Company Profile

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

USD
NASDAQ
CEO: Richard A. Fair
Employees: 67
https://www.enliventherapeutics.com
Asset Summaries
Latest generated summaries for ELVN

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for ELVN.
Share price
$44.83
Market cap
$3.28B
Exchange
NASDAQ
Currency
USD
CEO
Richard A. Fair
Employees
67
IPO date
12/03/2020
Beta
0.245
Last dividend
$0.00
Day range
$44.64 – $45.90
52-week range
$14.79 – $62.32
1-day performance
0.45%
1-year performance
203.21%
Current drawdown (1Y)
-28.06%
CIK
0001672619
CUSIP
29337E102
ISIN
US29337E1029
Created
07/12/2025, 03:46:06
Last update
03/11/2026, 23:29:22

Track Enliven Therapeutics, Inc. with an AI analyst

See which prediction-market events move ELVN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.